Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

PDS Biotechnology Corp

PDSB Nasdaq SEC CIK 1472091
Follow PDS Biotechnology Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$9.8M −3.4% vs same quarter last year
EPS, diluted −$0.18 +14.3% vs same quarter last year
Operating cash flow −$2.8M +69.3% vs same quarter last year
Operating income −$6.5M +14.8% vs same quarter last year
Net income by quarter
−$10.7M
−$8M
−$8.5M
−$9.4M
−$9M
−$7.6M
−$7.3M
−$9.8M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$34.5M
FY24−$37.6M
FY23−$42.9M
FY22−$40.9M
FY21−$16.9M
FY20−$14.8M
FY19−$7M
FY18−$3.8M
FY17−$50.9M
FY16−$38.8M
FY15−$28.1M
FY14−$12.2M
FY13−$6.9M
FY12-
FY11-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$27.8M
FY24−$35.1M
FY23−$33.6M
FY22-
FY21-
FY20-
FY19-
FY18−$1.6M
FY17−$40.9M
FY16−$32.9M
FY15−$23.1M
FY14−$10.6M
FY13−$8.2M
FY12-
FY11-

News

1 story filed under PDS Biotechnology